July 12, 2016

Sienna Biopharmaceuticals Announces Second Closing of Series A Financing

June 20, 2016

Kite Pharma Expands Development of T-Cell Receptor (TCR) Therapies Targeting HPV-Associated Cancers in Partnership with the National Cancer Institute (NCI)

June 20, 2016

Kite Pharma Opens State-of-the-Art T-Cell Therapy Manufacturing Facility

June 16, 2016

Capricor Therapeutics Reports Positive 12-Month Data from the DYNAMIC Clinical Trial

June 6, 2016

Kite Pharma Presents Ongoing Complete Responses at 9 Months in Phase 1 of ZUMA-1 in Patients with Chemorefractory Non-Hodgkin Lymphoma

June 6, 2016

Kite Pharma Announces the First Meta-Analysis of Outcomes in Chemorefractory Diffuse Large B-Cell Lymphoma (SCHOLAR-1)

June 6, 2016

Kite/NCI Anti-CD19 CAR T-Cell Therapy Demonstrates Durable Complete Remissions in Advanced Non-Hodgkin Lymphoma

June 2, 2016

Kite Pharma and Cell Design Labs Announce Exclusive Research Collaboration Using Molecular ‘On/Off Switches’ for CAR T-Cell Immunotherapies

June 2, 2016

Cell Design Labs Executes Series of Private Financings

June 2, 2016

Kite Pharma and Cell Design Labs Announce Exclusive Research Collaboration Using Molecular ‘On/Off Switches’ for CAR T-Cell Immunotherapies

May 5, 2016

UroGen Pharma Announces Three Data Presentations Related to its Clinical Stage Uro-Oncology Candidates at the American Urology Association’s 2016 Annual Meeting

May 2, 2016

Kite Pharma Announces FDA Orphan Drug Designations for KTE-C19 in Five Additional Indications

April 28, 2016

Sienna Biopharmaceuticals Announces $34 Million Series A Financing

April 19, 2016

Arno Therapeutics to Focus Clinical Developmental Activities on Advanced Prostate Cancer in First-of-its-Kind Phase II Study of Onapristone in Combination with ZYTIGA

April 19, 2016

Kite Pharma Presents Updated Phase 1 Results from ZUMA-1 at the American Association of Cancer Research (AACR) Annual Meeting

April 4, 2016

Capricor Therapeutics Announces DSMB Recommends Continuation of HOPE-Duchenne Clinical Trial

March 21, 2016

Arno Therapeutics Advances Phase I/II Trial Evaluating Onapristone in Prostate Cancer to Phase II

March 17, 2016

Kite Pharma Announces Clinical Collaboration to Evaluate Two Novel Immunotherapies for Patients with Non-Hodgkin Lymphoma

March 17, 2016

Capricor Awarded $3.4 Million Grant from California Institute for Regenerative Medicine

March 16, 2016

Kite Pharma Announces Clinical and Manufacturing Updates on KTE-C19 and MAGE-A3 Product Candidates at the Annual Meeting of the American Association for Cancer Research (AACR)

March 15, 2016

Capricor Therapeutics Announces $4 Million Registered Direct Offering

February 22, 2016

Capricor Therapeutics Announces the First Patient with Duchenne Muscular Dystrophy-Related Cardiomyopathy Treated with CAP-1002 in the HOPE-Duchenne Phase I/II Clinical Trial

February 8, 2016

UroGen Pharma Strengthens Board of Directors and Senior Management Team

January 13, 2016

UroGen Pharma Strengthens Leadership Team and Expands Uro-Oncology Clinical Pipeline with Addition of TLR-7 Agonist Phase 2 Asset

January 13, 2016

Arno Therapeutics Completes $7.4 Million Common Stock Financing